Ares Trading S.a.

Merck Serono S. A.

Laboratoires Serono S.a.

Other

Merck Patent Gmbh

Calypso Biotech Sa

Christine Power

Richard Fagan

Christopher Benjamin Phelps

Amanda Proudfoot

Melanie Yorke

Christine Plater-Zyberk

Yolande Chvatchko

Ursula Boschert

Stephen Fitzgerald

Mark Douglas Davies

Olivier Leger

David Michalovich

Jacques Colinge

Achim Frauenschuh

Mark Ibberson

Horacio Gabriel Nastri

Christel Iffland

Philippe V Dupraz

Philippe Chatellard

Richard Joseph Fagan

Andrew Robert Davids

Qi An

Paul Bradfield

Markus Imhof

Mariastella De Tiani

Jadwiga Bienkowska

Laurent Magnenat

Laurence Goffin

Tania Maria Rodrigues

Kinsey Maundrell

Simon John White

Richard James Mitter

Melanie Yorke-Smith

Yolande Chvatchko Missotten

Gabriela Saborio

Yan Lavrovsky

Steven M Dunn

Maud Deruaz

Vincent Dechavanne

George Feger

Nigel Jenkins

Peter Hjelmstrom

Renata Pankiewicz

Gian Battista Bozzato

Richard James Inpharmatica Limited Mitter

Yolande Ares Trading SA Chvatchko

Richard Joseph Inpharmatica Limited Fagan

Christopher Benjamin Inpharmatica Limited Phelps

Ursula Ares Trading SA Boschert

David Inpharmatica Limited Michalovich

Richard Joseph Impharmatica Limited Fagan

Simon John Inpharmatica Limited White

The present invention relates to new proteins that bind to MMP9 and comprise at least one fragment of a heavy chain variable region and/or at least one fragment of a light chain variable region of an antibody. In particular, the MMP9 binding proteins according to the invention are able to neutralize MMP9 activity and are useful in the prevention and/or treatment of inflammatory and/or autoimmune diseases or cancers. In particular, the MMP9 binding proteins according to the invention are useful in diagnosis of MMP9-related disorders.

Antibodies specific for MMP9

The invention relates to monoclonal antibodies against human CXCR5 and to their use in the treatment of autoimmune or inflammatory diseases, as well as cancers.

Monoclonal antibody directed against CXCR5

The invention relates to the use of INSP035 for treatment and/or prevention of fibrotic diseases, in particular of scleroderma.

Treatment of fibrotic disease

Proteins (INSP141, INSP142, INSP143, and INSP144) identified as anthrax receptor-like proteins containing von Willebrand factor A (vWFA) and Anthrax receptor extracellular (ANT_IG) domains and the use of these proteins and nucleic acid sequences from the encoding genes in the diagnosis, prevention and treatment of disease are described.

[object Object]

This invention relates to a novel protein, termed INSP201, herein identified as a cell surface glycoprotein, and to the use of this protein and nucleic acid sequences from the encoding gene in the diagnosis, prevention and treatment of disease.

Cell surface glycoprotein

This invention relates to novel uses of a protein sequence (INSP052EC), herein identified as an immunoglobulin domain-containing cell surface recognition, in the diagnosis, prevention and treatment of diseases, in particular those related to the excessive expression and/or secretion of cytokines.

Method of treatment comprising administration of a cytokine antagonist molecule

The present invention relates to sCD164 variants and therapeutic uses thereof, in particular for treating or preventing inflammatory or autoimmune disorders.

Soluble CD164 polypeptides

This invention relates to the novel protein, termed INSP163, herein identified as a secreted protein containing a jelly-roll fold, in particular, as a member of the TNF (tumor necrosis factor)-like family of cytokines, specifically as a C1q-like protein and to the use of this protein and nucleic acid sequence from the encoding gene in the diagnosis, prevention and treatment of disease.

Isolated INSP 163 protein

A novel CXC-chemokine binding protein is cloned from the salivary glands of. Compounds prepared in accordance with the present invention can be used as anti-inflammatory and immuno-modulatory compounds and in the treatment or prevention of CXC-chemokine-related diseases.

The invention relates to the use of SARP-1 for the preparation of a medicament for the treatment and/or prevention of scleroderma, in particular of systemic sclerosis.

Method for treating liver cirrhosis or interstitial pulmonary fibrosis

The invention relates to the use of osteoprotegerin for treatment and/or prevention of fibrotic diseases, in particular of scleroderma.

Use of osteoprotegerin for the treatment and/or prevention of fibrotic disease

A novel CC-chemokine binding protein is isolated from the saliva of. Compounds prepared in accordance with the present invention can be used as anti-inflammatory compounds and in the treatment or prevention of CC-chemokine-related diseases.

CC-chemokine binding tick proteins

This invention relates to a novel protein (INSP052), herein identified as an immunoglobulin domain-containing cell surface recognition molecule and to the use of this proteins and nucleic acid sequences from the encoding gene in the diagnosis, prevention and treatment of disease. The invention also relates to the identification of the extracellular domain of INSP052.

Cytokine antagonist molecules

This invention relates to a novel protein (INSP002), herein identified as a secreted protein that is a member of the Dan family of the cystine-knot fold cytokine superfamily and to the use of this protein and nucleic acid sequences from the encoding genes in the diagnosis, prevention and treatment of disease.

Cystine-knot fold protein

A novel CC-chemokine binding protein is isolated from the saliva of. Compounds prepared in accordance with the present invention can be used as anti-inflammatory and immunomodulatory compounds and in the treatment or prevention of CC-chemokine-related diseases.

Growing community of inventors

Thoiry, France

Christine Power